CLEARWATER, Fla.--(BUSINESS WIRE)--Bovie Medical Corporation (NYSE:BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma ®, a patented surgical product marketed ...
Caplacizumab is a von Willebrand factor (vWF)-directed antibody fragment designed to inhibit the interaction between vWF and platelets.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback